You may be weighing the two drugs because your friend on letrozole conceived while your clomid cycle did not, because your gynecologist offered clomid but your fertility specialist recommends letrozole, or because you simply want to understand why a fifty-year-old standard has a new challenger. The aim of this post is a clean, side-by-side comparison of clomid vs letrozole using the trial data we actually have, with the cases where each drug still wins.
Most of the time, in 2026, when a person with polycystic ovary syndrome (PCOS) sits across from a reproductive endocrinologist (RE) and asks why they were prescribed one of these drugs and not the other, the honest answer for PCOS specifically points to letrozole. The reason is a single landmark trial published in 2014. We will start there, then walk through where the picture is more nuanced.
What did the PALO trial find for clomid vs letrozole?
The most important piece of evidence in this comparison is the Pregnancy in Polycystic Ovary Syndrome (PALO) trial, published in the New England Journal of Medicine in 2014 by Richard Legro and colleagues.1 The trial enrolled 750 women with PCOS and infertility, randomized them to either letrozole or clomiphene, and followed them for up to five treatment cycles. The primary outcome was live birth.
| Outcome | Letrozole | Clomiphene |
|---|---|---|
| Cumulative live-birth rate | 27.5% | 19.1% |
| Ovulation rate per cycle | 61.7% | 48.3% |
| Multiple-pregnancy rate | 3.4% | 7.4% |
| Endometrial thickness on trigger day | Better preserved | Lower, more thin-lining cycles |
The eight-percentage-point absolute gap in live birth, in favor of letrozole, is large for a fertility trial. It is the difference between roughly one in five and one in four people taking the drug going home with a baby after five cycles. The lower multiples rate, the higher ovulation rate, and the better lining are all consistent with the mechanistic differences between the two drugs, which I cover in the clomid pillar post and the letrozole pillar post.
A 2018 Cochrane systematic review of aromatase inhibitors for PCOS reached the same conclusion, with no signal of harm.3 A 2015 meta-analysis by Roque and colleagues in Gynecological Endocrinology pooled multiple comparative trials and again found letrozole superior on ovulation, pregnancy, and live birth in PCOS.6 The 2023 International Evidence-Based Guideline for PCOS endorses letrozole as the first-line ovulation induction drug, in preference to clomiphene.5
How does each drug work, clomid vs letrozole?
Letrozole is an aromatase inhibitor. Aromatase is the enzyme that converts androgens to estrogens. A short course of letrozole briefly lowers estrogen production, the brain reads this as a signal to release more follicle-stimulating hormone (FSH), and that stronger FSH pulse recruits a follicle. The drug has a half-life of about 45 hours and is essentially cleared from the body before ovulation, which means the uterine lining and cervical mucus are not exposed to the drug during the fertile window.
Clomid (clomiphene citrate) is a selective estrogen receptor modulator (SERM). It blocks estrogen receptors at the hypothalamus, which produces the same "estrogen looks low, push more FSH" signal. The trouble is that clomid does not block receptors only at the hypothalamus. It blocks them throughout the body, including at the endometrium and cervix. The drug also has a longer half-life of five to seven days, so it is still acting on those tissues during the fertile window.
The mechanism difference is the mechanistic reason letrozole wins on lining and on cervical mucus, and it shapes most of the rest of the comparison.
How do the side effects of clomid and letrozole compare?
Both drugs produce side effects that are mostly tied to brief estrogen withdrawal, so there is real overlap. The differences are in duration, in a few drug-specific effects, and in clinical-experience patterns.
Hot flashes: Both drugs cause them. Frequency is comparable across trials, in the rough range of ten to twenty percent of cycles, with letrozole symptoms more compressed into the dosing window because the drug clears faster.
Headache, breast tenderness, bloating: Common to both, with similar frequencies. Most are mild and self-limited.
Visual changes: This is a clomid-specific effect. Blurring, spots, light sensitivity, or new floaters affect approximately one to two percent of clomid cycles.2 It is a same-day call to your clinic and a reason to stop the cycle, because rare progression to more lasting visual symptoms is the safety concern. Letrozole does not produce this effect.
Mood symptoms: Both drugs can cause mood changes. In practice, clomid mood symptoms run longer and are reported as more disruptive, partly because the drug is in the system longer. Clinically, when I see a patient struggling badly with mood on clomid, switching to letrozole frequently improves it. The trial data on mood is less crisp than the trial data on lining, but the pattern is consistent enough across patients that it shows up in most clinical reviews.
Thin endometrial lining: Approximately fifteen percent of clomid cycles end with a lining less than 7mm on trigger day.3 Letrozole almost never produces this, because the drug is cleared before the lining is fully exposed to rising estrogen. This is the cleanest mechanistic win for letrozole.
Hostile cervical mucus: Clomid reduces fertile-quality cervical mucus in some cycles, which can blunt sperm transit. Letrozole does not produce this effect to the same degree. For couples on timed intercourse, this is a real consideration; for couples on intrauterine insemination (IUI), the cervix is bypassed and the mucus issue matters less.
Which drug has a higher risk of twins?
Both drugs raise the multiple-pregnancy rate above the natural background rate of roughly one to two percent, because both recruit more than one follicle in some cycles. The trial numbers are:
- Clomid twins: approximately 8% to 10% of pregnancies.
- Letrozole twins: approximately 3% to 4% of pregnancies.
- Triplets: rare on both, slightly higher on clomid.
For many couples, the twin difference is not what decides the prescription. For some, particularly those with PCOS and a high antral follicle count, the lower letrozole multiples rate is meaningful. Either way, cycle monitoring and cancellation criteria (typically three to four mature follicles) are the real safety net, not the drug choice alone.
When does clomid still match or beat letrozole?
PALO settled the question for PCOS. It did not settle the question for every infertility population.
Unexplained infertility: The AMIGOS trial (Diamond et al. 2015) compared letrozole, gonadotropins, and clomid in couples with unexplained infertility. The lowest live-birth rate in that trial was the letrozole arm.2 The clean PCOS signal does not transfer to unexplained infertility. For couples without PCOS, the choice between the two oral drugs is more open, and your RE will weigh personal history, lining, sperm parameters, and tubal status before recommending one over the other.
Prior clomid responders: If you conceived on clomid before and you are back trying for a second baby, your own history is the cleanest piece of evidence in the room. Switching to letrozole for the sake of switching is rarely the right move when you have already shown the body responds to clomid.
Cost and access: Letrozole is off-label for ovulation induction in the United States and several other countries. This affects insurance coverage in some plans and pharmacy stocking in others. Clomid is universally familiar to gynecologists, universally stocked, and often cheaper at the pharmacy counter. In settings where letrozole is genuinely harder to obtain, clomid remains the practical choice. Globally, clomid is still the most-prescribed oral ovulation induction drug, and that is not the wrong answer in those settings.
Patient preference: If a patient tolerated clomid well in the past and prefers to continue with what they know, that is a legitimate factor. Drug switching has a small psychological cost that is worth weighing against the expected gain.
Clomid or letrozole: which is better for PCOS?
For PCOS the picture is clean. The 2023 International Evidence-Based Guideline for the Assessment and Management of PCOS states that letrozole should be considered the first pharmacological treatment for ovulation induction in anovulatory infertility in PCOS, in preference to clomiphene, when there are no contraindications.5 ASRM, ESHRE, and NICE all align with this position.
In clinical language, that means for a PCOS patient with no contraindications and access to letrozole, I almost always start there. The reasons are the better live birth rate, the better lining behavior, the lower multiples rate, and the cleaner pharmacokinetic profile through the fertile window. None of those reasons are subtle. They were all measured directly in PALO.
If you have PCOS and you were prescribed clomid first by a general gynecologist, that is not necessarily wrong, particularly outside a specialist fertility center. It is, however, worth asking whether letrozole would be a better fit when you next see your team.
How do doctors choose between clomid and letrozole?
I want to be transparent about the decision logic, because most patients have only seen the outcome (the prescription) and not the reasoning. A rough version of how I think through it:
- PCOS, no contraindication, letrozole available: almost always letrozole.
- PCOS, prior conception on clomid: often stay with clomid, particularly if monitoring showed reasonable lining and ovulation.
- Unexplained infertility: depends on age, partner sperm, tubes; sometimes clomid first, sometimes letrozole, sometimes straight to IUI with either.
- Documented thin lining on clomid in a prior cycle: switch to letrozole.
- Severe clomid mood symptoms in a prior cycle: switch to letrozole.
- Cost or access constraints: whichever drug the patient can reliably obtain and afford.
The decision is rarely close once the specifics are on the table. The hardest cases are the ones where a patient has done two cycles of clomid, has ovulated and not conceived, and the question is whether to do another cycle of clomid or switch. I cover that decision in when clomid stops working and switching from clomid to letrozole.
What should I ask my doctor about clomid vs letrozole?
- Why this drug for me, given PCOS and the current guidelines.
- If we are on clomid, are we monitoring lining and follicles so we can switch quickly if needed.
- What is the dose escalation plan if I do not ovulate.
- How many cycles before we change drug or step up.
- What is your threshold for adding IUI rather than continuing timed intercourse.
If you and your partner are deciding together, the cycle before the cycle is the calmest moment to align on what "switching" or "stepping up" would mean later.
What's next
- If you are about to start either drug for the first time: clomid, how it works or letrozole for PCOS
- If you are looking at the side effect profile specifically: clomid side effects, what to expect
- If you are on clomid cycle three or four and re-evaluating: when clomid stops working
- If your RE has suggested switching: switching from clomid to letrozole, what changes
- If this cycle failed and you need support before the next decision: when things don't go to plan
Sources
- Legro RS, Brzyski RG, Diamond MP, Coutifaris C, Schlaff WD, Casson P, et al. Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. New England Journal of Medicine 2014;371(2):119-129. https://www.nejm.org/doi/full/10.1056/NEJMoa1313517
- Diamond MP, Legro RS, Coutifaris C, et al. Letrozole, gonadotropin, or clomiphene for unexplained infertility. New England Journal of Medicine 2015;373(13):1230-1240. https://www.nejm.org/doi/full/10.1056/NEJMoa1414827
- Franik S, Eltrop SM, Kremer JA, Kiesel L, Farquhar C. Aromatase inhibitors (letrozole) for subfertile women with polycystic ovary syndrome. Cochrane Database of Systematic Reviews 2018;(5):CD010287. https://doi.org/10.1002/14651858.CD010287.pub3
- Brown J, Farquhar C. Clomiphene and other antioestrogens for ovulation induction in polycystic ovary syndrome. Cochrane Database of Systematic Reviews 2016;(12):CD002249. https://doi.org/10.1002/14651858.CD002249.pub5
- Teede HJ, Tay CT, Laven JJE, et al. Recommendations from the 2023 International Evidence-Based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Fertility and Sterility 2023;120(4):767-793. https://doi.org/10.1016/j.fertnstert.2023.07.025
- Roque M, Tostes AC, Valle M, Sampaio M, Geber S. Letrozole versus clomiphene citrate in polycystic ovary syndrome: systematic review and meta-analysis. Gynecological Endocrinology 2015;31(12):917-921. https://doi.org/10.3109/09513590.2015.1096337
Common questions
Is clomid or letrozole better for PCOS?
For PCOS the evidence favors letrozole. In the 2014 PALO trial of 750 women with PCOS, letrozole produced a 27.5% cumulative live-birth rate versus 19.1% for clomiphene, plus a higher ovulation rate and lower multiples rate. The 2023 International Evidence-Based Guideline for PCOS endorses letrozole as the first-line ovulation induction drug, in preference to clomiphene, when there are no contraindications.
Why does letrozole cause less thin lining than clomid?
Letrozole has a half-life of about 45 hours and is essentially cleared from the body before ovulation, so the uterine lining is not exposed to the drug during the fertile window. Clomid has a longer half-life of five to seven days and blocks estrogen receptors throughout the body, including the endometrium. Approximately fifteen percent of clomid cycles end with a lining less than 7mm on trigger day; letrozole almost never produces this.
Which drug has a higher risk of twins, clomid or letrozole?
Clomid carries the higher twin risk, at roughly 8% to 10% of pregnancies, compared with about 3% to 4% for letrozole. Both raise the multiple-pregnancy rate above the natural background of one to two percent because both can recruit more than one follicle. Triplets are rare on both drugs, slightly higher on clomid. Cycle monitoring and cancellation criteria, typically three to four mature follicles, are the real safety net.
When does clomid still work as well as letrozole?
For unexplained infertility the PCOS advantage does not transfer; in the AMIGOS trial the letrozole arm had the lowest live-birth rate. Clomid also remains the sensible choice if you previously conceived on it, since your own history is strong evidence, or where letrozole is harder to obtain or more costly. Patient preference for a familiar drug is also a legitimate factor.
Are the side effects of clomid and letrozole different?
There is real overlap, since most side effects come from brief estrogen withdrawal: hot flashes, headache, breast tenderness, and bloating occur with both at similar frequencies. Visual changes such as blurring or floaters are clomid-specific, affecting about one to two percent of clomid cycles, and warrant a same-day call to your clinic. Clomid mood symptoms also tend to run longer and feel more disruptive because the drug stays in the system longer.